HEPION PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
HEPION PHARMACEUTICALS, INC. (HEPA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2024-08-13
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-06-30 was 0.00 shares.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-31 was 340.00K shares.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-03-31 was 0.00 shares.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-06-30 was 0.00 shares.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 31.53K shares.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|
| 2024-06-30 | 0.00 shares 10-Q · filed 2024-08-13 | 340.00K shares derived: sum of 2 quarters · filed 2024-08-13 | |
| 2024-03-31 | 340.00K shares 10-Q · filed 2024-08-13 | ||
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-06-29 | ||
| 2019-12-31 | 31.53K shares 10-K · filed 2020-05-14 | ||
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | 0.00 shares 10-Q · filed 2020-08-12 | |
| 2019-03-31 | 0.00 shares 10-Q · filed 2020-06-29 | ||
| 2018-12-31 | 0.00 shares 10-K · filed 2020-05-14 | ||
| 2018-03-31 | 0.00 shares 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |